| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 12/11/2001 | US6329365 Inhibitors of interleukin-1β converting enzyme |
| 12/11/2001 | US6329362 Modulation cell adhesion the compounds are able to inhibit the binding of alpha 4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders. |
| 12/11/2001 | US6329355 Method for inhibiting the growth of cancers |
| 12/11/2001 | US6329354 Administering bone active phosphonate, administering estrogen hormone |
| 12/11/2001 | US6329352 Method and composition for treating sleep apnea |
| 12/11/2001 | US6329344 Urea derivative of alkylene dioxyfuran ethers |
| 12/11/2001 | US6329000 Extract of pine needle and the use thereof |
| 12/11/2001 | US6328999 Ginkgo biloba leaf extracts with a reduced 4′-O-methylpyridoxine and biflavone content |
| 12/11/2001 | US6328997 Magnesium bicarbonate |
| 12/11/2001 | US6328993 Oral administration form for an acid liable active proton pump inhibitor |
| 12/11/2001 | US6328989 Use of bicozamycin for the manufacture of a medicament for treating infections with enterohemorrhagic e. coli |
| 12/11/2001 | US6328963 For purifying or assaying human mp52 produced b genetic engineering techniques |
| 12/11/2001 | US6328958 Deleted adenovirus vectors and methods of making and administering the same |
| 12/11/2001 | CA2329482C Recombinant antibodies specific for tnf-.alpha. |
| 12/11/2001 | CA2226292C Substituted benzolactam compounds as substance p antagonists |
| 12/11/2001 | CA2136094C Methods and compositions for increasing the sensitivity of a cell to a dna damaging agent |
| 12/11/2001 | CA2117953C Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| 12/11/2001 | CA2050477C T cell growth factor |
| 12/08/2001 | CA2349776A1 Novel crystalline forms of (3s-trans)-2-¬3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2h-1-benzopyran-7-yl|-4-(trifluoromethyl)-benzoic acid |
| 12/06/2001 | WO2001092892A2 Methods to identify compounds that modulate rage |
| 12/06/2001 | WO2001092571A1 Notch 4 and schizophrenia |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092526A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | WO2001092490A2 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | WO2001092485A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE |
| 12/06/2001 | WO2001092333A2 Use of adnf for enhancing learning and memory |
| 12/06/2001 | WO2001092312A1 Peptide substrate identified by type bont/b botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 12/06/2001 | WO2001092308A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | WO2001092294A2 Therapeutic anti-melanoma compounds |
| 12/06/2001 | WO2001092292A2 Ghrelin analogs |
| 12/06/2001 | WO2001092282A2 Methods and compositions for treating flaviviruses and pestiviruses |
| 12/06/2001 | WO2001092274A2 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 12/06/2001 | WO2001092267A2 Dihydropyridine compounds for the inhibition of calcium-influx |
| 12/06/2001 | WO2001092264A1 Adenosine a2a receptor antagonists |
| 12/06/2001 | WO2001092260A1 4-(2-phenylthiazol-5-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 12/06/2001 | WO2001092259A1 1,4-diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof |
| 12/06/2001 | WO2001092256A1 2,7-naphthyridine derivatives |
| 12/06/2001 | WO2001092254A1 Method for replacing organic solvents contained in clathrate crystals |
| 12/06/2001 | WO2001092241A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors |
| 12/06/2001 | WO2001092239A1 Biciclic cyclohexylamines and their use as nmda receptor antogonists |
| 12/06/2001 | WO2001092238A1 Amorphous oxazole coumpound and its use as cox-2 inhibitor |
| 12/06/2001 | WO2001092230A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 12/06/2001 | WO2001092229A1 TNF-α PRODUCTION INHIBITORS |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001092224A1 Indole derivatives with vascular damaging activity |
| 12/06/2001 | WO2001092218A2 Polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | WO2001092210A1 Compounds for modulating the rage receptor |
| 12/06/2001 | WO2001092204A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| 12/06/2001 | WO2001092201A1 Substituted phenylpropionic acid derivatives |
| 12/06/2001 | WO2001091808A2 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 12/06/2001 | WO2001091797A2 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds |
| 12/06/2001 | WO2001091789A2 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | WO2001091783A2 Methods and compositions for producing a neurosalutary effect in a subject |
| 12/06/2001 | WO2001091780A1 Neuroprotective peptides |
| 12/06/2001 | WO2001091774A2 Method of treating chronic ulcers |
| 12/06/2001 | WO2001091773A2 Method of stimulating hair growth |
| 12/06/2001 | WO2001091754A1 Protein kinase inhibitors |
| 12/06/2001 | WO2001091750A1 Use of a celecoxib composition for fast pain relief |
| 12/06/2001 | WO2001091749A1 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
| 12/06/2001 | WO2001091739A2 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 12/06/2001 | WO2001070683A3 3-substituted-4-pyrimidone derivatives |
| 12/06/2001 | WO2001056532A3 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 12/06/2001 | WO2001053351A3 Apoptin bindendes protein |
| 12/06/2001 | WO2001051474A3 Polypharmacophoric agents |
| 12/06/2001 | WO2001049717A3 Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001046178A3 Substituierte bisindolymaleimide |
| 12/06/2001 | WO2001045732A3 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
| 12/06/2001 | WO2001041704A3 Method for the prevention and/or treatment of atherosclerosis |
| 12/06/2001 | WO2001040229A3 Method for producing epinastine hydrochloride in the high-melting crystal modification |
| 12/06/2001 | WO2001034201A3 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 12/06/2001 | WO2001034138B1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 12/06/2001 | WO2001032864A3 Gpcr-kd5 polypeptides and dna sequences thereof |
| 12/06/2001 | WO2001032127A3 Method and compositions for treating pulmonary diseases |
| 12/06/2001 | WO2001022977A3 Echinacea supplement and method of manufacture |
| 12/06/2001 | WO2001021605A8 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food |
| 12/06/2001 | WO2001018042A3 Apoptosis proteins |
| 12/06/2001 | WO2001017999A3 Amino-triazolopyridine derivatives |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001010847A8 Novel integrin receptor antagonists |
| 12/06/2001 | WO2001001972A3 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 12/06/2001 | WO2001000193A3 Zinc ionophores as anti-apoptotic agents |
| 12/06/2001 | WO2000077233A3 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/06/2001 | WO2000077206A3 The myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | WO2000077018A3 Purine derivatives |
| 12/06/2001 | US20010049435 Myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | US20010049382 Or nicotinic acid esters |
| 12/06/2001 | US20010049377 Glucocortiocoid-selective antiinflammatory agents |
| 12/06/2001 | US20010049371 Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases |
| 12/06/2001 | US20010049353 Stimulating secretion of pancreatic juices |
| 12/06/2001 | US20010049349 Antioxidant enhancement of therapy for hyperproliferative conditions |
| 12/06/2001 | US20010049348 Interaction of NMDA receptor with protein tyrosine phosphatase |
| 12/06/2001 | US20010049142 A rapid, simple-to-use method to differentiate nondividing cells by fusing two different cells and then purifying them without antibiotic or metabolic selection; kits with two nontoxic dyes and instructions; antitumor agents |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010048952 Mixture of aloe vera, collagen, chromium compounds and linoleic acid |
| 12/06/2001 | US20010048948 Intestine health; immunology; mixture containing whey |
| 12/06/2001 | US20010048919 Virus clearance of neoplastic cells from mixed cellular compositions |
| 12/06/2001 | US20010048917 Skin equivalent and methods of forming and using same |
| 12/06/2001 | US20010048914 Radioactive therapeutic liposomes |